首页> 外文期刊>Journal of proteome research >Proteomic analysis of microvesicles derived from human mesenchymal stem cells
【24h】

Proteomic analysis of microvesicles derived from human mesenchymal stem cells

机译:人间充质干细胞来源的微囊泡的蛋白质组学分析

获取原文
获取原文并翻译 | 示例
           

摘要

Mesenchymal stem cells (MSCs) have emerged as a promising means for treating degenerative or incurable diseases. Recent studies have shown that microvesicles (MVs) from MSCs (MSC-MVs) contribute to recovery of damaged tissues in animal disease models. Here, we profiled the MSC-MV proteome to investigate their therapeutic effects. LC-MS/MS analysis of MSC-MVs identified 730 MV proteins. The MSC-MV proteome included five positive and two variable known markers of MSCs, but no negative marker, as well as 43 surface receptors and signaling molecules controlling self-renewal and differentiation of MSCs. Functional enrichment analysis showed that cellular processes represented by the MSC-MV proteins include cell proliferation, adhesion, migration, and morphogenesis. Integration of MSC's self-renewal and differentiation-related genes and the proteome of MSC-conditioned media (MSC-CM) with the MSC-MV proteome revealed potential MV protein candidates that can be associated with the therapeutic effects of MSC-MVs: (1) surface receptors (PDGFRB, EGFR, and PLAUR); (2) signaling molecules (RRAS/NRAS, MAPK1, GNA13/GNG12, CDC42, and VAV2); (3) cell adhesion (FN1, EZR, IQGAP1, CD47, integrins, and LGALS1/LGALS3); and (4) MSC-associated antigens (CD9, CD63, CD81, CD109, CD151, CD248, and CD276). Therefore, the MSC-MV proteome provides a comprehensive basis for understanding the potential of MSC-MVs to affect tissue repair and regeneration.
机译:间充质干细胞(MSCs)已经成为治疗退行性或不治之症的有前途的手段。最近的研究表明,在动物疾病模型中,来自MSC(MSC-MVs)的微泡(MVs)有助于受损组织的恢复。在这里,我们介绍了MSC-MV蛋白质组,以研究其治疗效果。 MSC-MV的LC-MS / MS分析确定了730 MV蛋白。 MSC-MV蛋白质组包括MSC的五个阳性和两个可变的已知标记物,但没有阴性标记,以及控制MSC自我更新和分化的43个表面受体和信号分子。功能富集分析表明,以MSC-MV蛋白为代表的细胞过程包括细胞增殖,粘附,迁移和形态发生。 MSC的自我更新和分化相关基因以及MSC条件培养基(MSC-CM)的蛋白质组与MSC-MV蛋白质组的整合揭示了可能与MV-MV的治疗作用相关的潜在MV蛋白候选物:(1 )表面受体(PDGFRB,EGFR和PLAUR); (2)信号分子(RRAS / NRAS,MAPK1,GNA13 / GNG12,CDC42和VAV2); (3)细胞粘附(FN1,EZR,IQGAP1,CD47,整联蛋白和LGALS1 / LGALS3); (4)MSC相关抗原(CD9,CD63,CD81,CD109,CD151,CD248和CD276)。因此,MSC-MV蛋白质组学为理解MSC-MV影响组织修复和再生的潜力提供了全面的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号